Enoxaparin sodium

Category	SARS-CoV
CAS	679809-58-6
Description	Enoxaparin sodium is an anticoagulant medication used for the prevention of blood clots such as deep vein thrombosis (DVT), and also for the treatment of blood vessel complications in patients with angina and heart attack.

Quotation Now

Solubility	10 mM in DMSO (In vitro)
Appearance	White to off-white (Solid)
Storage	4°C, protect from light * In solvent : -80°C, 6 months -20°C, 1 month (protect from light)
Complexity	2410
Exact Mass	1134.0069961
In Vitro	Enoxaparin (0-70 µg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E Cell Viability Assay Cell Line: HEK293T TMPRSS2 cells, hAEc Concentration: 0, 8.8, 35, 70 µg/mL Incubation Time: 90 min Result: Significantly inhibited TMPRSS2 activity at the 90 min incubation period at 35 and 70 µg/mL, enhanced AAT inhibition of TMPRSS2 activity, and augmented AAT inhibition of HCoV-229E infection of hAEc.
In Vivo	Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat. Animal Model: Adult male Wistar rats (350-450 g, TBI-treated) Dosage: 0 mg/kg, 1 mg/kg Administration: SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction Result: Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active Caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat.
Target	Factor Xa; Thrombin; SARS-CoV
XLogP3-AA	-10.8